-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2020, many patients with rheumatism have unfortunately been infected with the new coronavirus
This is a comparative cohort study that uses the multicenter research network (TriNetX) in the United States to extract data on all adult RA patients and non-RA patients with COVID-19 from January 20, 2020 to April 11, 2021
The study included 9730 RA patients with confirmed COVID-19 and 656,979 non-RA patients with COVID-19
The mortality rate of the RA cohort, hospitalization rate, ICU occupancy rate, mechanical ventilation, severe COVID-19, acute kidney injury, renal replacement therapy/hemodialysis, acute respiratory distress syndrome-ARDS, ischemic stroke, venous thromboembolism-VTE, and sepsis risk are higher than those of non-RA Patients with new crowns are higher than non-RA patients with new crowns.
Comparison of risk of outcome before and after matching between RA cohort and non-RA cohort
This study found that before matching, the risk of all adverse outcomes in the RA cohort was higher than that in the non-RA cohort.
The risk of VTE and sepsis in the RA cohort was consistently elevated, indicating that RA is an independent risk factor
Original source:
Rahul Raiker.
Leave a message here